دورية أكاديمية
Bioequivalence assessment of two Ticagrelor formulations under fasting condition in healthy Pakistani subjects.
| العنوان: | Bioequivalence assessment of two Ticagrelor formulations under fasting condition in healthy Pakistani subjects. |
|---|---|
| المؤلفون: | Hashmi N; Naghma Hashmi Center for Bioequivalence Studies and Clinical Research, Dr. Panjwani Center for Molecular Medicine and Drug Research International, Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan., Jawaid M; Masood Jawaid Director Medical Affairs, PharmEvo Private Limited, 402, Business Avenue, Block-6, P.E.C.H.S., Shahrah-e-Faisal, Karachi, Pakistan., Shah MR; Muhammad Raza Shah Center for Bioequivalence Studies and Clinical Research, Dr. Panjwani Center for Molecular Medicine and Drug Research International, Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan. |
| المصدر: | Pakistan journal of medical sciences [Pak J Med Sci] 2023 Nov-Dec; Vol. 39 (6), pp. 1647-1651. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Professional Medical Publications Country of Publication: Pakistan NLM ID: 100913117 Publication Model: Print Cited Medium: Print ISSN: 1682-024X (Print) Linking ISSN: 1681715X NLM ISO Abbreviation: Pak J Med Sci Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Karachi, Pakistan : Professional Medical Publications, [2000- |
| مستخلص: | Objective: To investigate the Bioequivalence of Anplag® 90mg (Ticagrelor) tablet and Brilinta® 90 mg (Ticagrelor) tablet under fasting conditions in healthy Pakistani subjects. Method: This was an open-label, cross-over, randomized, single-dose, two-period, single-center Bioequivalence Study conducted at Center of Bioequivalence Studies and Clinical Research (CBSCR), ICCBS, University of Karachi, Karachi, Pakistan from September 2020 to January 2021. This was an open-label, randomized, single-dose, two-period, cross-over Bioequivalence Study. After randomization, a single dose of Ticagrelor 90mg tablet (test or reference drug) were administered orally in 1:1 ratio to each subject under fasting conditions. Seven days washout period was kept between the two periods in order to avoid carry over. Blood samples were then taken up to 48th hours post-dose. Point estimates and 90% confidence intervals (CI) for the ratio of the log-transformed values were calculated. Bioequivalence assessment of both, the reference and the test drugs were based on the primary Pharmacokinetic PK metrics including peak maximum concentration (Cmax), area under the curve (AUC) from zero to last quantifiable concentration (AUClast), and AUC from zero to infinity (AUCtotal) after log-transformation of data with ANOVA. In this bioequivalence study, the primary pharmacokinetic parameters were assessed for both Ticagrelor and its Active Metabolite (AR-C124910XX). Safety endpoints were evaluated by monitoring adverse events (AEs). Results: The 90% Confidence Intervals (CIs) of the Geometric Mean Ratio for primary PK parameters including C max , AUC last , and AUC total all were within the accepted bioequivalence range of 80%- 125%. In the current study, no serious adverse events were reported. Conclusion: Our results showed that the two tested formulations of Ticagrelor tablets were bioequivalent and well tolerated. Trial Registration: ClinicalTrials.gov Identifier: NCT04941196. Competing Interests: Conflict of Interest: Regarding this research, no conflict of interest exists. (Copyright: © Pakistan Journal of Medical Sciences.) |
| References: | Thromb Haemost. 2003 May;89(5):783-7. (PMID: 12719773) Clin Drug Investig. 2012 Feb 1;32(2):87-97. (PMID: 22168538) Cardiovasc Interv Ther. 2014 Oct;29(4):324-33. (PMID: 24935072) J Clin Med. 2020 Jul 01;9(7):. (PMID: 32630233) Circulation. 2004 Jun 29;109(25):3171-5. (PMID: 15184279) Expert Opin Pharmacother. 2011 Jun;12(8):1285-95. (PMID: 21254864) J Drug Assess. 2013 Mar 15;2(1):30-9. (PMID: 27536435) Drugs. 2011 May 7;71(7):909-33. (PMID: 21568367) Eur Heart J. 2020 Oct 1;41(37):3495-3497. (PMID: 33085966) Expert Opin Drug Metab Toxicol. 2016 Dec;12(12):1491-1502. (PMID: 27715344) Circulation. 2020 Mar 3;141(9):e139-e596. (PMID: 31992061) J Am Coll Cardiol. 2014 Dec 23;64(24):e139-e228. (PMID: 25260718) Circ Cardiovasc Genet. 2010 Dec;3(6):556-66. (PMID: 21079055) Ther Clin Risk Manag. 2018 Jan 17;14:129-140. (PMID: 29398917) |
| فهرسة مساهمة: | Keywords: Bioavailability; Bioequivalence; Pharmacokinetic; Ticagrelor |
| سلسلة جزيئية: | ClinicalTrials.gov NCT04941196 |
| تواريخ الأحداث: | Date Created: 20231108 Latest Revision: 20231109 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10626117 |
| DOI: | 10.12669/pjms.39.6.8203 |
| PMID: | 37936786 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!